These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 7542804)

  • 1. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.
    Larder BA; Kemp SD; Harrigan PR
    Science; 1995 Aug; 269(5224):696-9. PubMed ID: 7542804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
    Tisdale M; Kemp SD; Parry NR; Larder BA
    Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5653-6. PubMed ID: 7685907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zidovudine and lamivudine: results of phase III studies.
    Staszewski S
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S57. PubMed ID: 8595510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility.
    Harrigan PR; Kinghorn I; Bloor S; Kemp SD; Nájera I; Kohli A; Larder BA
    J Virol; 1996 Sep; 70(9):5930-4. PubMed ID: 8709214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3TC/AZT: just another combination.
    GMHC Treat Issues; 1995 Dec; 9(12):2. PubMed ID: 11362997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase.
    Wainberg MA; Drosopoulos WC; Salomon H; Hsu M; Borkow G; Parniak M; Gu Z; Song Q; Manne J; Islam S; Castriota G; Prasad VR
    Science; 1996 Mar; 271(5253):1282-5. PubMed ID: 8638110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retention of marked sensitivity to (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-di hydroquin oxaline-2(1H)-thione (HBY 097) by an azidothymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the combined presence of quinoxaline HBY 097 and 2',3'-dideoxy-3'-thiacytidine (lamivudine).
    Balzarini J; Pelemans H; Riess G; Roesner M; Winkler I; De Clercq E; Kleim JP
    Biochem Pharmacol; 1998 Mar; 55(5):617-25. PubMed ID: 9515572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group.
    Larder BA; Kohli A; Bloor S; Kemp SD; Harrigan PR; Schooley RT; Lange JM; Pennington KN; St Clair MH
    J Virol; 1996 Sep; 70(9):5922-9. PubMed ID: 8709213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lamivudine (3TC) approved for combination use with AZT.
    James JS
    AIDS Treat News; 1995 Dec; (no 236):1-5. PubMed ID: 11363049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
    Katlama C; Ingrand D; Loveday C; Clumeck N; Mallolas J; Staszewski S; Johnson M; Hill AM; Pearce G; McDade H
    JAMA; 1996 Jul; 276(2):118-25. PubMed ID: 8656503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy.
    Iversen AK; Shafer RW; Wehrly K; Winters MA; Mullins JI; Chesebro B; Merigan TC
    J Virol; 1996 Feb; 70(2):1086-90. PubMed ID: 8551567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
    Staszewski S; Loveday C; Picazo JJ; Dellarnonica P; Skinhøj P; Johnson MA; Danner SA; Harrigan PR; Hill AM; Verity L; McDade H
    JAMA; 1996 Jul; 276(2):111-7. PubMed ID: 8656502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination 3TC/AZT therapy shows promise.
    AIDS Clin Care; 1995 Mar; 7(3):22. PubMed ID: 11362192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo.
    Nijhuis M; Schuurman R; de Jong D; van Leeuwen R; Lange J; Danner S; Keulen W; de Groot T; Boucher CA
    J Infect Dis; 1997 Aug; 176(2):398-405. PubMed ID: 9237704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase.
    Boucher CA; Cammack N; Schipper P; Schuurman R; Rouse P; Wainberg MA; Cameron JM
    Antimicrob Agents Chemother; 1993 Oct; 37(10):2231-4. PubMed ID: 7504909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel point mutation at position 156 of reverse transcriptase from feline immunodeficiency virus confers resistance to the combination of (-)-beta-2',3'-dideoxy-3'-thiacytidine and 3'-azido-3'-deoxythymidine.
    Smith RA; Remington KM; Preston BD; Schinazi RF; North TW
    J Virol; 1998 Mar; 72(3):2335-40. PubMed ID: 9499094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidine.
    Kemp SD; Shi C; Bloor S; Harrigan PR; Mellors JW; Larder BA
    J Virol; 1998 Jun; 72(6):5093-8. PubMed ID: 9573280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy.
    Richman DD; Havlir D; Corbeil J; Looney D; Ignacio C; Spector SA; Sullivan J; Cheeseman S; Barringer K; Pauletti D
    J Virol; 1994 Mar; 68(3):1660-6. PubMed ID: 7509000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
    Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
    Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An interview with Charles A.B. Boucher, MD, PhD. Interview by Mark Mascolini.
    Boucher CA
    J Int Assoc Physicians AIDS Care; 1995 Nov; 1(10):30-5. PubMed ID: 11362972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.